Early and Late Prognosis in Patients With Guillain-Barre Syndrome

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with Guillain-Barre syndrome.

Detailed Description
-----------------
This is a multicenter study(approximately three) with over 450 subjects.Clinical data were collected by consulting the patient's electronic history. The data included demographic information, blood biochemical markers, clinical characteristics and electromyography. All participants provided their written informed consent to participate in this study.

Official Title
-----------------
Early and Late Prognosis in Patients With Guillain-Barre Syndrome

Conditions
-----------------
Guillain-Barre Syndrome

Intervention / Treatment
-----------------
* Drug: Intravenous Immunoglobulins, Human
* Drug: Methylprednisolone 500 MG Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients fulfilled clinical, biological, and electrophysiology criteria for Guillain-barre syndrome. Exclusion Criteria: nonidiopathic Guillain-barre syndrome and Miller Fisher syndrome
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: immunoglobulin group<br>This group of patients was treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days | Drug: Intravenous Immunoglobulins, Human<br>* patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days<br>|
| Experimental: methylprednisolone group<br>This group of patients was treated with methylprednisolone 500 MG Injection | Drug: Methylprednisolone 500 MG Injection<br>* patients were treated with methylprednisolone<br>|
| No Intervention: control group<br>This group of patients was treated without immunoglobulin or hormone | |
| Experimental: mixed group<br>This group of patients was treated both with intravenous immunoglobulin and methylprednisolone. | Drug: Intravenous Immunoglobulins, Human<br>* patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days<br>Drug: Methylprednisolone 500 MG Injection<br>* patients were treated with methylprednisolone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the severity of Guillain-barre syndrome | The Guillain-barre syndrome disability score is a wide scale for the severity of Guillain-barre syndrome (0, optimal health; 1, minor symptoms, able to run; 2, able to walk unaided 10 m, unable to run; 3, able to walk 10 m across an open space with help; 4 bedridden or wheelchair users; 5, require assisted ventilation; 6, dead).The higher the score, the worse the prognosis. | baseline, at 1 week, at 26 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Guillain-barre syndrome, prognosis